Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 13/20 | 0.50 |
| ▸ | INSR | P06213 | 12/20 | 0.50 |
| ▸ | IGF1R | P08069 | 12/20 | 0.50 |
| ▸ | PTK2B | Q14289 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 4/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.46 |
| ▸ | EML4 | Q9HC35 | 3/20 | 0.46 |
| ▸ | STK10 | O94804 | 2/20 | 0.46 |
| ▸ | ABL1 | P00519 | 2/20 | 0.46 |
| ▸ | LCK | P06239 | 2/20 | 0.46 |
| ▸ | FYN | P06241 | 2/20 | 0.46 |
| ▸ | FES | P07332 | 2/20 | 0.46 |
| ▸ | YES1 | P07947 | 2/20 | 0.46 |
| ▸ | HCK | P08631 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL520521 | 0.95 | ALK (0.48) | ALKINSRIGF1RPTK2BKDM4E | |
| SCHEMBL519761 | 0.95 | ALDH1A1 (0.50) | ALKINSRIGF1RPTK2BKDM4E | |
| SCHEMBL29517345 | 0.95 | ALDH1A1 (0.50) | ALKINSRIGF1RPTK2BKDM4E | |
| SCHEMBL10205071 | 0.93 | L3MBTL3 (0.46) | ALKINSRIGF1RKDM4EMAPT | |
| SCHEMBL13177796 | 0.92 | ALK (0.44) | ALKINSRIGF1RPTK2BKDM4E | |
| SCHEMBL23533701 | 0.91 | ALK (0.43) | ALKINSRIGF1RPTK2BEGFR | |
| SCHEMBL520789 | 0.90 | ALDH1A1 (0.46) | ALKINSRIGF1RPTK2BKDM4E | |
| SCHEMBL24073828 | 0.90 | ALK (0.48) | ALKINSRIGF1RPTK2BKDM4E | |
| SCHEMBL520836 | 0.89 | L3MBTL1 (0.57) | ALKINSRIGF1RGAAMAPT | |
| SCHEMBL10206202 | 0.89 | L3MBTL3 (0.53) | ALKINSRIGF1REGFRHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113024454-B | Synthesis method of brigatinib intermediate | 浙江工业大学 | 2022-09-09 | — | — | CN | claimed |
| EP-4725487-A1 | NOVEL COMPOUND AND PREPARATION METHOD THEREFOR | Astrion Inc. (KR) | 2026-04-15 | — | — | EP | disclosed |
| EP-4725488-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BRAIN TUMOR | Astrion Inc. (KR) | 2026-04-15 | — | — | EP | disclosed |
| CN-120774958-A | Preparation method of Bragg nylon | 江苏工程职业技术学院 | 2025-10-14 | — | — | CN | disclosed |
| EP-3965803-B1 | SMALL-MOLECULE FOCAL ADHESION KINASE (FAK) INHIBITORS | DANA FARBER CANCER INST INC (US) | 2025-08-20 | — | — | EP | disclosed |
| US-12365696-B2 | Small-molecule focal adhesion kinase (FAK) inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| CN-119735613-A | Crystalline forms of 5-chloro-N4- [2- (dimethylphosphoryl) phenyl ] -N2- { 2-methoxy-4- [4- (4-methylpiperazin-1-yl) piperidin-1-yl ] phenyl } pyrimidine-2, 4-diamine | 武田药品工业株式会社 | 2025-04-01 | — | — | CN | disclosed |
| WO-2024253476-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BRAIN TUMOR | 주식회사 에스트리온 | 2024-12-12 | — | — | WO | disclosed |
| WO-2024253475-A1 | NOVEL COMPOUND AND PREPARATION METHOD THEREFOR | 주식회사 에스트리온 | 2024-12-12 | — | — | WO | disclosed |
| US-20240409609-A1 | REVERSIBLE LYSINE COVALENT MODIFIERS OF EGFR AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. | 2024-12-12 | — | — | US | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
| US-20100099658-A1 | DI(ARYLAMINO)ARYL COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-04-22 | — | — | US | disclosed |
| EP-2172461-A1 | DI(ARYLAMINO)ARYL COMPOUND | Astellas Pharma Inc. (JP) | 2010-04-07 | — | — | EP | disclosed |
| EP-2172461-A1 | DI(ARYLAMINO)ARYL COMPOUND | Astellas Pharma Inc. (JP) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009143389-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009143389-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| US-20090221555-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS | CEPHALON, INC. (US) | 2009-09-03 | — | — | US | disclosed |
| WO-2009032703-A1 | 2- (HET) ARYLAMINO-6-AMINOPYRIDINE DERIVATIVES AND FUSED FORMS THEREOF AS ANAPLASTIC LYMPHOMA KINASE INHIBITORS | IRM LLC (BM) | 2009-03-12 | — | — | WO | disclosed |
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2008-06-05 | — | — | US | disclosed |
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12365696-B2 | Small-molecule focal adhesion kinase (FAK) inhibitors | PTK2, CTTN, TNK2 | ALK 1473/4885INSR 4003/4885IGF1R 1563/4885 |
| US-20090221555-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS | ALK, MET, RET | ALK 1/4885INSR 241/4885IGF1R 66/4885 |
| US-20100099658-A1 | DI(ARYLAMINO)ARYL COMPOUND | ERBB4, EGFR, ALK | ALK 3/4885INSR 607/4885IGF1R 47/4885 |
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | TYMS, TYMP, DPYD | ALK 3200/4885INSR 2899/4885IGF1R 4633/4885 |
| US-20240409609-A1 | REVERSIBLE LYSINE COVALENT MODIFIERS OF EGFR AND USES THEREOF | EGFR, ERBB2, ERBB3 | ALK 174/4885INSR 2993/4885IGF1R 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.